Nov 8 (Reuters) - Orexigen Therapeutics Inc OREX.O :
* Orexigen Therapeutics Inc - Orexigen expects Valeant to file for regulatory approvals in both countries in first half of 2017
* Valeant Pharma through a wholly owned subsidiary, will commercialize Contrave in Australia and New Zealand
* Orexigen Therapeutics - Orexigen will supply Contrave tablets to Valeant for an agreed transfer price and certain potential sales milestone payments
* Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant for Vontrave (naltrexone HCL/bupropion HCL extended release) in Australia and New Zealand Source text for Eikon: ID:nPn7f5h4Ma Further company coverage: OREX.O